



society of hematologic oncology

PRÉ-PROGRAMME

5ÈME ÉDITION 2026

CONGRÈS EN HÉMATOLOGIE
du 14 au 16 octobre 2026

SORBONNE UNIVERSITÉ
AUDITORIUM DU CICSU, 75005 PARIS



Mandatée par
l'association ARCADE

LE COMITÉ SCIENTIFIQUE



Présidente : **Mauricette MICHALLET** (Hématologue, Centre Léon Bérard, Lyon)

- **Amine BELHABRI** (Hématologue, Centre Léon Bérard, Lyon)
- **Sylvain CHOQUET** (Hématologue, Hôpital Pitié-Salpêtrière, Paris)
- **Jean-Jacques KILADJIAN** (Hématologue, Hôpital Saint-Louis, Paris)
- **Xavier LELEU** (Hématologue, Centre Hospitalier Universitaire de Poitiers, Poitiers)
- **François-Xavier MAHON** (Hématologue, Institut Bergonié, Bordeaux)
- **Anne-Sophie MICHALLET** (Hématologue, Centre Léon Bérard, Lyon)
- **Sophie PARK** (Hématologue, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble)
- **Christian RECHER** (Hématologue, Institut Universitaire du Cancer de Toulouse, Toulouse)
- **Philippe ROUSSELOT** (Hématologue, Centre Hospitalier de Versailles, Versailles)
- **Pierre SESQUES** (Hématologue, Centre Hospitalier Lyon Sud, Lyon)

Wednesday 14th october 2026

- 10h00 - 10h30 INTRODUCTION**
Mauricette MICHALLET (President of the Scientific Committee), (Hematology, Lyon)
- What are the innovations in myeloid diseases since the last SOHO France 2025 conference?
- Hagop Kantarjian (Oncology Hematology, Houston - USA)
- 10h30 - 11h45 SESSION 1: MYELOPROLIFERATIVE NEOPLASMS**
Chair: Jean-Jacques KILADJIAN (Hematology, Paris)
- Essential thrombocythemia: from therapeutic frugality to new horizons
Jean-Jacques Kiladjian (Hematology, Paris) – 20min
 - Skin carcinomas complicating treatments for NMPs
Hélène Pasquer (Hematology, Paris) – 20min
 - Contribution of AI in the NMP
Vincent Alcazer (Hematology, Pierre-Bénite) – 20 min
 - Discussion – 15 min
- 11h45 - 12h45 TAILORED THERAPEUTIC STRATEGIES FOR MYELOFIBROSIS PATIENTS WITH CYTOPENIA, WHERE WE STAND IN 2026 ?**
Chair: Mauricette MICHALLET (Hematology, Lyon)
- Addressing cytopenias in myelofibrosis: from assessment to treatment
Laurence LEGROS (Hematology, Paris)
 - Optimizing therapeutic strategies for clinical practice
Eolia BRISSOT (Hematology, Paris)
 - Discussion
- 12h45 - 13h45 LUNCH BREAK & MEET OUR PARTNERS** 
- 13h45 - 15h00 SESSION 2 : MYELOYDYSPLASTIC SYNDROMES**
Chair: Sophie PARK (Hematology, Grenoble)
- Management of clonal hematopoiesis in clinical practice: GFM recommendations
Aline Renneville (Pharmacy, Paris) – 20 min
 - Optimization of pre and post transplantation therapies in mds
Marie Robin (Hematology, Paris) – 20 min
 - How to treat CMML: should we target stem or differentiated cells?
Raphael Itzykson (Hematology, Paris) – 20 min
 - Discussion – 15 min
- 15h00 - 15h30 CALL FOR ABSTRACT**
- 15h30 - 16h30 2nd SYMPOSIUM**
- 16h30 - 16h50 COFFEE BREAK & MEET OUR PARTNERS** 
- 16h50 - 17h20 ROUNDTABLE DISCUSSION: ACUTE MYELOID LEUKEMIA**

PRÉ-PROGRAMME

17h20 - 18h35

SESSION 3: ACUTE MYELOID LEUKEMIA

Chairs: Amine BELHABRI (Hematology, Lyon) & Arnaud PIGNEUX (Hematology, Bordeaux)

- Functional precision medicine for acute myeloid leukemia

Raphael Itzykson (Hematology, Paris) – 20 min

- BIG Experience in France: results of BIG-1 and future BIG-2 program

Sarah Bertoli (Hematology, Toulouse) – 20 min

- Results from PARADIGM study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Amir Fathi (Hematology, Boston - USA) – 20 min

- Discussion – 15 min

Thursday 15th october 2026

09h30 - 10h25

SESSION 4: ACUTE LYMPHOBLASTIC LEUKEMIA

Chair: Aurélie CABANNES (Hematology, Versailles)

- First results of the ALL TARGET observatory

Aurélie Cabannes (Hematology, Versailles) – 15 min

- GRAALL recommendations for relapsed ALL

Marie Balsat (Hematology, Lyon) – 15 min

- New development of immunotherapies in B-ALL

Nicolas Boissel (Hematology, Paris) – 15 min

- Discussion – 15 min

10h25 - 10h45

COFFEE BREAK & MEET OUR PARTNERS



10h45 - 11h45

3rd SYMPOSIUM

11h45 - 12h55

SESSION 5: CAR-T CELLS

Chair: Pierre SESQUES (Hematology, Lyon)

- Estimating the real price of CAR-T cells in France: from list price to net price

Carole-Anne Brugère (Calym/Hematology, Lyon) – 15 min

- Recommendations from the LYSA centered on the place of the CAR-T cells and data on the L2: comparison vs SOC & Axi-liso: sequence?

Benoît Tessoulin (Hematology, Nantes) – 15 min

- Impact of T cell characteristics on CAR-T cell therapy / Fitness of T in the CAR-T cells? Present and future

Estelle Bourbon (Hematology, Lyon) – 15 min

- MM: CAR-T cells then bispecific? bispecific then CAR-T cells? Upcoming sequence?

Alexis Talbot (Immuno-hematology, Paris) – 15 min

- Discussion – 15 min

12h55 - 13h55

LUNCH BREAK & MEET OUR PARTNERS



13h55 - 14h55

4th SYMPOSIUM

PRÉ-PROGRAMME

14h55 - 16h05 **SESSION 6: MULTIPLE MYELOMA**

Chair: Xavier LELEU (Hematology, Poitiers)

- Towards personalized medicine and cure in multiple myeloma: precision biomarkers and beyond

Anaïs Schavgoulidze (Medical biology, Toulouse) – 15 min

- Response or resistance! Based on interesting data from RESISTEC. Do we have a predictive response marker, is it useful for real life?

Ludovic Martinet (Research, Toulouse) – 15 min

- NDMM TE and TI. The IT will replace the autograft, can you convince us?

Cyrille Touzeau (Hematology, Nantes) – 15 min

- Tomorrow's IT, new ADCs, new CAR-T, Trispe. With the MAJESTEC 3 and TEC LILLE data, do we still need to develop always more, for what? what are the limits of current TTTs that justify developing more, whether it is safety, efficacy, or cost

Alexis Talbot (Immuno-hematology, Paris) – 15 min

- Discussion – 15 min

16h05 - 16h20 **COFFEE BREAK & MEET OUR PARTNERS**



16h20 - 16h50 **CALL FOR ABSTRACT**

16h50 - 17h20 **SHORT-TALKS**

17h20 - 18h20 **SESSION 7: LYMPHOMAS**

Chair: Sylvain CHOQUET (Hematology, Paris)

- Intravascular NHL

Antoine Bonnet (Hematology, Nantes) – 15 min

- Primary mediastinal NHL

Vincent Camus (Hematology, Rouen) – 15 min

- Relapse/refractory Hodgkin lymphoma

Cedric Rossi (Hematology, Dijon) – 15 min

- Discussion – 15 min

Friday 16th october 2026

10h00 - 11h15 **SESSION 8: CHRONIC MYELOID LEUKEMIA**

Chair: François-Xavier MAHON (Hematology, Bordeaux)

- Development of machine learning applied to CML: prognostic and predictive factors

Vincent Alcazer (Hematology, Pierre-Bénite) – 20 min

- New molecules in CML

François-Xavier Mahon (Hematology, Bordeaux) – 20 min

- Individualizing front line therapy of chronic phase CML

Delphine Réa (Hematology, Paris) - 20 min

- Discussion – 15 min

11h15 - 11h30 **COFFEE BREAK & MEET OUR PARTNERS**



11h30 - 12h30 **5th SYMPOSIUM**

- 12h30 - 13h45** **SESSION 9: CELL THERAPY AND TRANSPLANTATION**
Follow up and treatments after allo-HSCT for hematological malignancies
Chair: Anne HUYNH (SFGM-TC president) (Hematology and transplantation, Toulouse)
- Post allo-HSCT monitoring?
- Léonardo Magro (Hematology and Transplantation, Lille) - 20 min
- Prophylactic treatments after allo-HSCT
- Raynier Devillier (Hematology and Transplantation, Marseille) - 20 min
- Treatments of relapse after allo-HSCT
- Michael Loschi (Hematology and Transplantation, Nice) - 20 min
- Discussion - 15 min
- 13h45 - 14h45** **LUNCH BREAK & MEET OUR PARTNERS** 
- 14h45 - 14h55** **AWARD CEREMONY - CALL FOR ABSTRACT**
- 14h55 - 15h10** **SHORT-TALK**
- 15h10 - 16h25** **SESSION 10: CHRONIC LYMPHOCYTIC LEUKEMIA**
Chair: Anne-Sophie MICHALLET (Hematology, Lyon)
- Should all patients be treated with a fixed duration of CLL as a first-line treatment?
- Emmanuelle Ferrant (Hematology, Lyon) - 20 min
- Is there hope for treating Richter syndrome with new innovative therapies?
- Pierre Feugier (Hematology, Nancy) - 20 min
- Is immunochemotherapy still the gold standard for first-line treatment in MW?
- Cécile Tomowiak (Hematology, Poitiers) - 20 min
- Discussion - 15 min
- 16h25 - 16h40** **TAKE HOME MESSAGE**